NasdaqGM:GPCRPharmaceuticals
Structure Therapeutics (GPCR) Valuation After Positive Phase 2b Aleniglipron Data And Upcoming Phase 3 Program
Structure Therapeutics (GPCR) moved into focus after publishing detailed Phase 2b ACCESS data for its oral GLP-1 candidate aleniglipron in Nature Medicine, alongside presentations at the American Diabetes Association’s 86th Scientific Sessions.
See our latest analysis for Structure Therapeutics.
Despite the positive ACCESS data and a busy conference schedule in recent weeks, Structure Therapeutics' share price has come under pressure. The 90 day share price return is down 33.49% and the year...